Key Decisions and Approvals

The Board of Directors meeting commenced at 2:45 PM and concluded at 3:35 PM on July 23, 2026. The Board considered and approved the following matters:

1. Unaudited Standalone and Consolidated Financial Results along with the Limited Review Report for the quarter ended June 30, 2026

2. Re-Appointment of Internal Auditor for the Financial Year 2026-27

Financial Results - Standalone (Quarter ended June 30, 2026)

Revenue Performance

  • Revenue from operations: ₹225.66 Crores (Unaudited)
  • Other Income: ₹3.51 Crores (Unaudited)
  • Total Revenue: ₹229.17 Crores (Unaudited)

Expense Breakdown

  • Cost of materials consumed: ₹58.86 Crores
  • Purchase of stock-in-trade: ₹0.03 Crores
  • Changes in inventories: ₹0.24 Crores
  • Employee benefits expense: ₹37.16 Crores
  • Finance cost: ₹1.26 Crores
  • Depreciation and amortization expense: ₹11.23 Crores
  • Other expenses: ₹53.76 Crores
  • Total Expenses: ₹162.54 Crores

Profitability Metrics

  • Profit before exceptional items and income tax: ₹66.63 Crores
  • Exceptional Items: None (₹0 Crores)
  • Profit after exceptional items and before tax: ₹66.63 Crores
  • Tax expense: ₹(16.46) Crores
  • Profit for the period: ₹50.17 Crores
  • Other comprehensive income: ₹0.48 Crores
  • Total comprehensive income: ₹50.65 Crores

Capital Structure and Per Share Data

  • Paid-up equity share capital (Face value of ₹10 each): ₹159.17 Crores
  • Earnings per share (Basic): ₹3.15 (not annualized)
  • Earnings per share (Diluted): ₹3.14 (not annualized)

Financial Results - Consolidated (Quarter ended June 30, 2026)

Revenue Performance

  • Revenue from operations: ₹240.02 Crores (Unaudited)
  • Other Income: ₹4.15 Crores (Unaudited)
  • Total Revenue: ₹244.17 Crores (Unaudited)

Expense Breakdown

  • Cost of materials consumed: ₹61.88 Crores
  • Purchase of stock-in-trade: ₹0.03 Crores
  • Changes in inventories: ₹0.25 Crores
  • Employee benefits expense: ₹39.61 Crores
  • Finance cost: ₹1.35 Crores
  • Depreciation and amortization expense: ₹12.49 Crores
  • Other expenses: ₹60.98 Crores
  • Total Expenses: ₹176.59 Crores

Profitability Metrics

  • Profit before exceptional items, share of profit of associate and income tax: ₹67.58 Crores
  • Exceptional Items: None (₹0 Crores)
  • Profit before share of profit of associate and income tax: ₹67.58 Crores
  • Share of profit of associate: ₹0.71 Crores
  • Profit before tax: ₹68.29 Crores
  • Tax expense: ₹(16.96) Crores
  • Profit for the period: ₹51.33 Crores
  • Other comprehensive income: ₹0.39 Crores
  • Total comprehensive income: ₹51.72 Crores

Segment-wise Performance

  • Diagnostic Testing Services Revenue: ₹226.21 Crores
  • Imaging Services Revenue: ₹13.48 Crores
  • Others Revenue: ₹0.33 Crores
  • Total Segment Revenue: ₹240.02 Crores

Segment Profitability

  • Diagnostic Testing Services profit before tax: ₹61.90 Crores
  • Imaging Services profit before tax: ₹1.26 Crores
  • Others profit before tax: ₹0.27 Crores

Capital Structure and Per Share Data

  • Paid-up equity share capital (Face value of ₹10 each): ₹159.17 Crores
  • Earnings per share (Basic): ₹3.23 (not annualized)
  • Earnings per share (Diluted): ₹3.22 (not annualized)

Entities Included in Consolidated Results

The consolidated financial results include the following entities:

  • Thyrocare Technologies Limited (Holding Company)
  • Nueclear Healthcare Limited (Subsidiary)
  • Pulse Hitech Health Services (Ghatkopar) LLP (Subsidiary)
  • Think Health Diagnostic Private Limited (Subsidiary)
  • Thyrocare Laboratories (Tanzania) Limited (Subsidiary)
  • Equinox Labs Private Limited (Associate)

Auditor Appointments

Internal Auditor Reappointment

  • Based on the recommendation of the Audit Committee, the Board approved the reappointment of M/s. Ernst & Young LLP, Chartered Accountants as Internal Auditors of the Company for the Financial Year 2026-27.
  • Date of Re-appointment: July 23, 2026
  • Term of Appointment: For the Financial year 2026-27

Statutory Auditor Review

  • Price Waterhouse Chartered Accountants LLP conducted the limited review of both standalone and consolidated financial results.
  • The auditors issued an unmodified conclusion on both standalone and consolidated financial results.

Additional Information

  • During the quarter ended June 30, 2026, the Company forfeited 3,733 equity stock options due to discontinuance of services of employees
  • The earning per share for quarter ended June 30, 2025 has been restated considering allotment of bonus shares and adjustment for outstanding stock options
  • The financial results are available on the company website (www.thyrocare.com) and stock exchange websites (BSE and NSE)